Vasoactive peptides in the skin

Journal of Investigative Dermatology Symposium Proceedings

Volumn 2, Issue 1, 1997, Pages 49-55

  Wallengren, Joanna ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Histamine; Neuropeptides; Neurotransmitters; Prostaglandin

Indexed keywords

BRADYKININ; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NEUROKININ A; NEUROPEPTIDE Y; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADRENERGIC TRANSMISSION; CHOLINERGIC TRANSMISSION; CONFERENCE PAPER; HUMAN; NEUROTRANSMISSION; REGULATORY MECHANISM; SKIN BLOOD FLOW; SKIN INFLAMMATION; VASOCONSTRICTION; VASODILATATION;

EID: 0030763867     PISSN: 10870024     EISSN: None     Source Type: Journal    
DOI: 10.1038/jidsymp.1997.11     Document Type: Conference Paper

References (55)

1. Abelous JE, Bardler E: Les substances hypotensives de I urine humaine normale. CR Seances Sac Biot Fil 66:511, J909
2. Amara SG, Jonas V, Rosenfeld MG: Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298:240-244
3. Andrade SO, Roche e Suva M: Purification of bradykinin by ion exchange chromatography. BiochemJ 64:701-705, 1956
4. Bayliss \VM: On the origin from the spinal cord of the vasodilator fibers of the hind limb and on the nature of these fibers. J Physiol (Land) 26:173-209, 1901
5. Bergström S, Samuelsson B: Isolation of prostaglandin E from calf thymus. Ada Chem Scand 17:S282-S287, 1963
6. Bernstein JE: Capsaicin and substance P. Clin Dermalol 9:497-503, 1992
7. Brain SD, Crossman DC, Buckley TL, Williams TJ: Endothelin-1: demonstration of potent effects on the microcirculation of humans and other species. J Cardiovasc Pruamacol 13(suppl 5):S147-149, 1989
8. Brain SD, Williams TJ.: Substance P regulates the vasodilator activity of calcitonin gene related peptide. Nature 335:73-75, 1988
9. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77-79, 1973
10. Bull HA, Bunker CB, Terenghi G, Springall DR, Zhao Y, Polak JM, Dowd PM: Endothelin-1 in human skin: Immunolocalization, receptor binding, mRNA expression, and effects on cutaneous microvascular endothelial cells. J Invest Dermatol 97:618-623, 1991
11. Bull HA, Hothersall J, Chowdhury N, Cohen J, Dowd PM: Neuropeptides induce release of nitric oxide from human dermal microvascular endothelial cells. J Invest Dermatol 106:655-660. 1996
12. Bunker CB, Foreman JC, Reavley C, O'Shaughenessy DJ, Dowd PM: Calcitonin gene-related peptide in treatment of severe Raynaud's phenomenon. Br J Dermatol 121(suppl 34):43-44, 1989
13. Burnstock G: Mechanism of interaction of peptide and non-peptide vascular neuroeffector systems. J Cardiovasc Pharmacol 10(suppl 12):574-581, 1987
14. Dale UM: Pharmacology and nerve ending. Proc R Soc Med 28:319-332, 1935
15. Edvinsson L, Ekblad E, Hâkanson R, Wahlestedt C: Neuropepode Y potentiates the effects of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol 83:519-525, 1984
16. Emadi-Khiav B, Mousoli M, Bronner Ch, Landry Y: Human and rat cutaneous mast cells: involvement of a G protein in the response to peptidergic stimuli. Eur J Pharmacol 272:97-102, 1995
17. Fitzgerald M: Capsaicin and sensory neurons: a review. Pain 15:109-130, 1983
18. Fjellner B, Hagermark O: Studies on pruritogenic and histamine-releasing effects of some putative neurotransmitters. Acla Derm Venereal (Stock!:) 61: 245-350, 1981
19. Foreman JC, Jordan CC: Histamine release and vascular changes induced by neu-. ropeptides. Agents Actions 13:2/3:105-116, 1983
20. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-376, 1980
21. Greaves M, Shuster S: Responses of skin blood vessels to bradykinin, histamine and S-hydroxytiyptamine.JPAyjiWCLomO 193:255-267, 1967
22. Greaves MW: Pharmacology and significance of nonsteroidal antiinflammatory drugs in the treatment of skin diseases. J Am Acaâ Dermalol 16:751-764, 1987
23. Hagermark Ö, Hökfelt T, Pernow B: Flare and itch induced by substance P in human skin. J Invest Dermatol 71:233-235, 1978
24. Harmar T, Lutz E: Multiple receptors for PACAP and V1P. Trends Phannacol Sei 15:97-99, 1994
25. Hanschuh W, Weihe E, Reinecke M: Pepridergic (neurotensin, VIP, substance P) nerve fibers in the skin. Immunohistochemical evidence of an involvement of neuropeptides in nociception, pruritus and inflammation. BrJ Dennatol 109(suppl 25):14-17, 1983
26. Hashim MA, Tadepalli AS: Cutaneous vasomotor effects of neuropeptide Y. Neuropeptides 29:263-271, 1995
27. Hiruma K, Koike T, Nakamura H, Sumida T, Maeda T, Tomioka H, Yoshida S, Fujita T: Somatostatin receptors on human lymphocytes and leukemia cells. Immunology 71:480-485, 1990
28. Itzhak Y: Blockade of sensitization to the toxic effects of cocaine in mice by nitric oxide synthase inhibitors. Pharmacol Toxicol 74:162-166, 1994
29. Johansson O, Vaalasti A: Immunohistochemical evidence for the presence of somatostatin-containing sensory ner\"e fibers in the human skin. Neiirosci Lett 73:225-230, 1987
30. Lembeck F, Holzer P: Substance P as neurogenic mediator of antidromic vasodilarion and neurogenic plasma extravasation. Naunyn Schtniedebergs Arch Pharmacol 310: 175-183, 1979
31. Linnick MD, Moskowitz MA: Identification of immunoreactive substance P in human and other mamalian endothelial cells. Peptides 10:957-965, 1989
32. Lundberg JM, Terenius L, Hôkfelt T, Martling CR, Tatemoto K, Mutt V, Polak J, Bloom S, Goldstein M: Neuropepdde Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Ada Physiol Scan} 16:477-480, 1982
33. Lynn B: Capsaicin: Actions on C-fiber afférents that may be involved in itch. Skin Pharmacol 5:9-13, 1992
34. Maggi CA, Patacchini R, Rovero P, Giachetti A: Tachykinin receptors and tachykinin receptor antagonists. J Avion Pliannacol 13:23-93, 1993
35. May V, Braas KM: Pituitary adenylate cyclase activating pol>-pepdde (PACAP). Regulation of sympadietic neuron neuropeptide Y and catecholamin expression. J Neurocliem 65:978-987, 1995
36. Mutt V, Said SI: Structure of the porcine vasoactive intestinal octacosapeptide: the aminoacide sequence; use of kallikrein in its determination. Ear J Biochem 42:581-589, 1974
37. Poyner D: Pharmacology of receptors for calcitonin gene-related pepdde and amylin. Trends Pharmacol Sei 16:424-428, 1995
38. Regoli D, Barabé J: Pharmacology of bradykinin and related kinins. Phannacol Rev 32:1:1-46, 1980
39. Said S, Mutt V: Polypeptide with broad biological activity: isolation from small intestine. Science 169:1217-1218, 1970
40. Schiffrin EL: Endothelin: Potential role hi hypertension and vascular hypertrophy. Hypertension 25:6:1135-1143, 1995
41. Snyder SH: Nitric oxide: First in a new class of neurotransmitters? Science 257:494-496, 1992
42. Stjarne L: Basic mechanisms and local modulation of nerve impulse-induced secretion of neurotransmitters from individual sympathetic nerve varicosities. Rev Phjsiol Bixhem Pharmacol 112:4-137, 1989
43. Sundler F, Brodin E, Ekblad E, Hâkanson R. Uddman R.: Sensory nerve fibers. Distribution of substance P, neurokinin A and calcitonin gene-related pepdde. In: Hâkanson R, Sundler F (eds.). Tachykinin Antagonists. Eisevier Science Publishers, BV:3-14, 1985
44. Sundler F, Hikanson R, Ekblad E, Uddman R, Wahlestedt C: Neuropeptide Y in the peripheral adrenergic and enteric nervous systems. Int Rev Cytol 102:243-269, 1986
45. Tatemoto K, Clarquist M, Mutt V: Neuropeptide Y: a novel brain peptide with structural similarities to peptide YY and pancreatic polypepride. Nature (Loud) 296:659-660, 1982
46. Tatemoto K, Lundberg J, M, Jömvall H, Mutt V: Neuropeptide K: Isolation, structure and biological activities of a novel brain tachykinin. Biochem Bicphys Res Commun 128:2:947-953, 1985
47. Wallengren J, Ekman R, Sundler F: Occurrence and distribution of neuropeptides in human skin. An immunocytochemical study on normal skin and blister fluid from inflammed skin. Ada Derm Venereal (Stockh) 67:185-192, 1987a
48. Wallengren J, Hâkanson R: Effects of substance P, neurokinin A and calcitonin gene related peptide in human skin and their involvement in sensory-mediated responses. Ear J Pharmacol 143:267-273, 1987b
49. Wallengren J, Hâkanson R, Andre'n-Sandbcrg A: Physiological factors influencing the substance P-evoked flare and wheal in human skin. Aâv Pain Res Tlier 20:63-69, 1992a
50. Wallengren J, Hâkanson R: Effects of capsaicin, bradykinin and prostaglandin E2 in die human skin. BrJ Dcrmatol 126:111-117, 1992b
51. Warren JB, Cockroft JR, Larkin SW, Kajekar R, Macrae A, Ghatei MA, Bloom SR: Pituitary adenylate cyclase activating polypeptide is a potent vasodilator ih humans. J Cardiovosc Phamacol 20:83-87, 1992
52. Weinstock JV, Blum AM: Release of substance P by granuloma eosionophils in response to secretagogues in murine Schistosomiasis mansoni. Cell Iinniitnol 125: 380-385, 1990
53. Williams TH, Morley J: Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature 246:215-217, 1973
54. Wilsoncroft P, Euzeger H, Brain S: Effect of neurokinin-j (NK^ receptor antagonist on oedema formation induced by tachykinins, carrageenin and an allergic response in guinea-pig skin. Neuropeptides 26:405-411, 1994
55. Yanagisawa M, Kurihara H, Kimura S, Tombe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415, 1988.